A53T-SNCA-BAC transgenic mouse exhibits multiple prodromal symptoms of Parkinson’s disease: Gastrointestinal dysfunction, hyposmia and RBD-like behavior.
Objective: To develop biomarkers and disease-modifying therapies for Parkinson’s disease, an animal model that recapitulates the early phase of the disease is indispensable. The aim…Evidence of gut dysbiosis in treatment-naïve de novo Parkinson’s disease
Objective: To determine the gut microbiome composition of treatment-naïve de novo Parkinson’s disease (PD) patients. Background: Over fifteen studies have independently demonstrated gut dysbiosis in…Intestinal Methanogen Overgrowth (IMO) More Prevalent than SIBO in Parkinson’s disease with Constipation: Preliminary Results
Objective: Our aim is to quantify the prevalence of small intestinal bacterial overgrowth (SIBO) and intestinal methanogen overgrowth (IMO) in PD subjects with constipation compared…The Presence of Efferent Brain-Gut Neuropathy Correlates with Severe Constipation in Parkinson’s disease
Objective: We aim to correlate brain-gut neuropathy amongst cortico- and lumbosacro-anorecal efferent pathways in PD subjects with severe constipation measured by prospective stool diary. Background:…Possible correlations between symptoms suggesting gastroparesis and dyskinesias in advanced Parkinson’s disease
Objective: The objective was to describe the spectrum of gastrointestinal complaints in a large cohort of patients with advanced Parkinson’s Disease (APD), who were repeatedly…Helicobacter pylori eradication in Parkinson’s disease: A double-blind randomized placebo-controlled study
Objective: To evaluate the effects of Helicobacter pylori eradication on PD symptoms. Background: Globally, H. pylori infection remains a common problem. Cross-sectional studies in Parkinson's disease (PD)…Effect of Lactobacillus casei supplementation on clinical response, gut microbiota and faecal metabolites in patients with Parkinson’s disease: A randomized, double-blind, placebo-controlled trial
Objective: To evaluate the effect of Lactobacillus casei strain Shirota (LcS) supplementation on symptoms, gut microbiota and faecal metabolites in patients with Parkinson's disease (PD).…Microbiome from Parkinson’s patients shows an increase in polyamines metabolism and differentially expresses microbial bacterial taxa compared to aged-matched normal controls
Objective: The goal of this study was to determine whether the microbiome from Parkinson’s disease (PD) has alterations in a) Polyamine metabolism and b) Expressed…The Gut Dysmotility Questionnaire (GDQ) for Parkinson’s disease: current development
Objective: To develop a questionnaire to screen for and monitor gastrointestinal symptoms in patients with Parkinson’s disease (PD), entitled Gut Dysmotility Questionnaire (GDQ). Background: Gut…Changes in fecal microbiota composition in patients with Huntington’s disease in China
Objective: Gut-brain axis has been associated with multiple brain disorders [1,2,3]. This study is to explore fecal microbiota changes in Huntington's disease (HD). Background: Huntington's…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 11
- Next Page »